Drug intelligence / Profile preview

CTH-502

Development stage: Preclinical
Lead developer: Cartherics
Modality: iPSCs → Pluripotent Stem Cells → Stem Cell Therapies → Cell Therapies, CAR-NK Cells → Other Engineered Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

CTH-502 is an allogeneic, induced pluripotent stem cell (iPSC)-derived natural killer (NK) cell therapy engineered with a chimeric antigen receptor (CAR) targeting Tissue Factor (TF). Developed by Cartherics, the product incorporates multiple gene knockouts to enhance its persistence and efficacy within the immunosuppressive tumor microenvironment. CTH-502 is being investigated for the treatment of various solid tumors and endometriosis, where Tissue Factor is often overexpressed. The therapy leverages an off-the-shelf approach by using iPSC-derived cells, allowing for standardized manufacturing and broader patient access.

Other names: CTH-502CTH502CTH 502

Targets

F3 (Tissue factor)

Beyond the preview

Go deeper on CTH-502.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CTH-502.

Explore the full profile